S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13

OptimizeRx Stock Forecast, Price & News

+0.44 (+1.61%)
(As of 07/1/2022 03:59 PM ET)
Today's Range
50-Day Range
52-Week Range
3,512 shs
Average Volume
194,396 shs
Market Capitalization
$505.17 million
P/E Ratio
Dividend Yield
Price Target

OptimizeRx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
132.1% Upside
$64.60 Price Target
Short Interest
13.44% of Float Sold Short
Dividend Strength
News Sentiment
0.61mentions of OptimizeRx in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From $0.01 to $0.45 Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.97 out of 5 stars

Computer And Technology Sector

362nd out of 936 stocks

Business Services, Not Elsewhere Classified Industry

52nd out of 146 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OptimizeRx logo

About OptimizeRx (NASDAQ:OPRX) Stock

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.

OPRX Stock News Headlines

This Options Expert is Giving Everything Away!
Trading champion Chuck Hughes has exposed the strategies of successful traders and handing them over to new traders like you! His guide “Options Trading Made Easy” now comes with a Trade of the Day from Chuck himself to help you develop a profitable, pro-level trading account!
Analysts Set OptimizeRx Co. (NASDAQ:OPRX) PT at $73.50
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate.
See More Headlines

Industry, Sector and Symbol

Business services, not elsewhere classified
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$61.29 million
Cash Flow
$0.13 per share
Book Value
$7.39 per share


Free Float
Market Cap
$505.17 million
Not Optionable

OptimizeRx Frequently Asked Questions

Should I buy or sell OptimizeRx stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OptimizeRx stock.
View analyst ratings for OptimizeRx
or view top-rated stocks.

What is OptimizeRx's stock price forecast for 2022?

6 analysts have issued 1-year price objectives for OptimizeRx's shares. Their OPRX stock forecasts range from $29.00 to $102.00. On average, they predict OptimizeRx's stock price to reach $64.60 in the next year. This suggests a possible upside of 132.1% from the stock's current price.
View analysts' price targets for OptimizeRx
or view top-rated stocks among Wall Street analysts.

How has OptimizeRx's stock price performed in 2022?

OptimizeRx's stock was trading at $62.11 at the beginning of 2022. Since then, OPRX shares have decreased by 55.2% and is now trading at $27.83.
View the best growth stocks for 2022 here

When is OptimizeRx's next earnings date?

OptimizeRx is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for OptimizeRx

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) issued its quarterly earnings data on Wednesday, May, 4th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.08) by $0.10. The business earned $13.73 million during the quarter, compared to the consensus estimate of $13.78 million. OptimizeRx had a negative trailing twelve-month return on equity of 1.76% and a negative net margin of 4.30%. During the same quarter in the prior year, the company earned ($0.01) earnings per share.
View OptimizeRx's earnings history

What guidance has OptimizeRx issued on next quarter's earnings?

OptimizeRx updated its FY 2022 earnings guidance on Monday, May, 16th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $80.00 million-$85.00 million, compared to the consensus revenue estimate of $81.83 million.

Who are OptimizeRx's key executives?

OptimizeRx's management team includes the following people:
  • Mr. William J. Febbo, CEO & Director (Age 53, Pay $1.04M) (LinkedIn Profile)
  • Mr. Edward Stelmakh C.M.A., M.B.A., MBA, CFO & COO (Age 56, Pay $505.64k)
  • Ms. Marion K Odence-Ford, Gen. Counsel & Chief Compliance Officer (Age 57, Pay $428.12k)
  • Mr. Douglas P. Baker, Exec. VP of Fin. & Accounting (Age 65) (LinkedIn Profile)
  • Mr. Andrew Jacob D'Silva, Sr. VP of Corp. Fin.
  • Mr. Todd Inman, Chief Technology Officer (Age 67)
  • Maira Alejandra, Media Relations Mang.
  • Ms. Sheryl Kearney, HR Mang.
  • Mr. Terence J. Hamilton, Sr. VP of Pharma (Age 57)
  • Mr. Stephen L. Silvestro, Chief Commercial Officer (Age 44) (LinkedIn Profile)

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

How do I buy shares of OptimizeRx?

Shares of OPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $27.83.

How much money does OptimizeRx make?

OptimizeRx (NASDAQ:OPRX) has a market capitalization of $505.17 million and generates $61.29 million in revenue each year. The company earns $380,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis.

How many employees does OptimizeRx have?

OptimizeRx employs 97 workers across the globe.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for OptimizeRx is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529.

This page (NASDAQ:OPRX) was last updated on 7/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.